Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1987 Oct;31(10):1585–1588. doi: 10.1128/aac.31.10.1585

Pharmacokinetics of cefpiramide in volunteers with normal or impaired renal function.

J E Conte Jr 1
PMCID: PMC174995  PMID: 3435107

Abstract

The pharmacokinetics of a single 2.0-g intravenous dose of cefpiramide in patients with normal or impaired renal function were studied. Serial concentrations in serum and urine were measured by using high-performance liquid chromatography, and the effect of the concentration in serum on protein binding was assessed. Thirty patients (ten with creatinine clearances of greater than 80 ml/min, ten with creatinine clearances between 10 and 80 ml/min, and ten on dialysis) were studied. The concentration-time curve of cefpiramide was best described by an open two-compartment model. The elimination half-lives in patients with normal or impaired renal function or those on dialysis were 5.41 +/- 1.44, 8.3 +/- 2.82, and 8.38 +/- 4.06 h, respectively, and the serum clearances in the same groups were 2.0 +/- 0.84, 1.29 +/- 0.45, and 2.04 +/- 1.10 liters/h, respectively. There were no significant differences in any of the parameters among the three groups of patients. In patients with normal or impaired renal function, protein binding varied between 93.0 +/- 1.3% at 304.4 micrograms/ml and 99.3 +/- 0.8% at 41.1 micrograms/ml and was linearly and inversely related to the cefpiramide concentration in serum. In patients on dialysis, protein binding was significantly lower (P less than 0.05) and varied between 88.5 +/- 7.1% at 173.4 micrograms/ml to 94.9 +/- 4.8% at 46.8 micrograms/ml. In patients with normal or abnormal renal function, renal cefpiramide clearance decreased linearly with declining renal function, whereas plasma clearance was maintained. Therefore, nonrenal elimination becomes more important as renal impairment progresses.

Full text

PDF
1585

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barry A. L., Jones R. N., Thornsberry C., Fuchs P. C., Ayers L. W., Gavan T. L., Gerlach E. H., Sommers H. M. Cefpiramide: comparative in-vitro activity and beta-lactamase stability. J Antimicrob Chemother. 1985 Sep;16(3):315–325. doi: 10.1093/jac/16.3.315. [DOI] [PubMed] [Google Scholar]
  2. Conte J. E., Jr, Zurlinden E. Column liquid chromatographic determination of cefpiramide in human serum and urine. J Chromatogr. 1987 Jul 3;417(2):452–457. doi: 10.1016/0378-4347(87)80144-5. [DOI] [PubMed] [Google Scholar]
  3. Fass R. J., Helsel V. L. In vitro activity of cefpiramide (SM-1652) against gram-negative bacilli. Diagn Microbiol Infect Dis. 1986 Jan;4(1):77–81. doi: 10.1016/0732-8893(86)90060-x. [DOI] [PubMed] [Google Scholar]
  4. Matsui H., Yano K., Okuda T. Pharmacokinetics of the cephalosporin SM-1652 in mice, rats, rabbits, dogs, and rhesus monkeys. Antimicrob Agents Chemother. 1982 Aug;22(2):213–217. doi: 10.1128/aac.22.2.213. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Nakagawa K., Koyama M., Matsui H., Ikeda C., Yano K., Nakatsuru N., Yoshinaga K., Noguchi T. Pharmacokinetics of cefpiramide (SM-1652) in humans. Antimicrob Agents Chemother. 1984 Feb;25(2):221–225. doi: 10.1128/aac.25.2.221. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Neu H. C., Chin N. X. The in vitro activity and beta-lactamase stability of cefpiramide compared with other beta-lactam antibiotics. Diagn Microbiol Infect Dis. 1985 Nov;3(6):479–488. doi: 10.1016/s0732-8893(85)80004-3. [DOI] [PubMed] [Google Scholar]
  7. Peterson L. R., Bean B., Fasching C. E., Korchik W. P., Gerding D. N. Pharmacokinetics, protein binding, and predicted extravascular distribution of moxalactam in normal and renal failure subjects. Antimicrob Agents Chemother. 1981 Sep;20(3):378–381. doi: 10.1128/aac.20.3.378. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Raghow G., Meyer M. C., Straughn A. B. Determination of free disopyramide plasma concentrations using ultrafiltration and enzyme multiplied immunoassay. Ther Drug Monit. 1985;7(4):466–471. doi: 10.1097/00007691-198512000-00019. [DOI] [PubMed] [Google Scholar]
  9. Smego R. A., Jr, Perfect J. R., Durack D. T. Combined therapy with amphotericin B and 5-fluorocytosine for Candida meningitis. Rev Infect Dis. 1984 Nov-Dec;6(6):791–801. doi: 10.1093/clinids/6.6.791. [DOI] [PubMed] [Google Scholar]
  10. Taylor E. H., Nelson D., Taylor R. D., Pappas A. A. Rapid sample preparation and high performance liquid chromatographic determination of total and unbound serum disopyramide. Ther Drug Monit. 1986;8(2):219–222. doi: 10.1097/00007691-198606000-00017. [DOI] [PubMed] [Google Scholar]
  11. Yogev R., Shulman S. T., Chadwick E. G., Davis A. T., Glogowski W. Once daily ceftriaxone for central nervous system infections and other serious pediatric infections. Pediatr Infect Dis. 1986 May-Jun;5(3):298–303. doi: 10.1097/00006454-198605000-00005. [DOI] [PubMed] [Google Scholar]
  12. Zysset T., Zeugin T. Comparison of the Amicon Centrifree micropartition system with the Sartorius SM 13249E Centrisart I device to determine protein free phenytoin concentrations. Ther Drug Monit. 1986;8(3):346–351. doi: 10.1097/00007691-198609000-00019. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES